MIRA INFORM REPORT
|
Report Date : |
23.11.2011 |
IDENTIFICATION DETAILS
|
Correct Name : |
DAESHIN PHARM CO., LTD. |
|
|
|
|
Registered Office : |
93-8, Yangjae 1-dong, Seocho-gu, Seoul, Korea, Zip Code 137-890 |
|
|
|
|
Country : |
South korea |
|
|
|
|
Date of Incorporation : |
19.05.1995 |
|
|
|
|
Com. Reg. No.: |
214-81-89068 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Wholesale of Other Chemical Materials and Chemical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment
Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
South Korea |
a1 |
a1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Basic
|
Company
Name |
DAESHIN PHARM
CO., LTD. (Korean Company
Name : “대신무약(주)”) |
|
Registered Address |
93-8, Yangjae 1-dong, Seocho-gu, Seoul,
Korea |
|
Zip Code |
137-890 |
|
Tel |
+82-2-572-5141 |
|
Fax |
+82-2-572-9431~2 |
|
E-mail |
|
|
Trading Address |
93-8, Yangjae 1-dong, Seocho-gu, Seoul,
Korea |
|
Tel |
+82-2-572-5141 |
|
Fax |
+82-2-572-9431~2 |
|
Type |
Import |
|
Industry |
Wholesale of Other Chemical Materials and Chemical Products |
|
Main Business |
Lactose, Ascorbic Acid |
|
Established (mm/dd/yyyy) |
05/19/1995 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Food or drug additives(12164500) |
|
Sell |
Ascorbic acid(12162201) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
CEO’s
|
Name |
Kim Yi-Yoon |
|
Address |
Suite 21-305, 369-1, Apgujeong-dong,
Gangnam-gu, Seoul, Korea |
|
Date of Birth |
01/01/1944 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
700,000,000 |
|
Employees |
15 |
|
Formation |
Co., Ltd by Shares |
|
Bank Details |
Hana Bank-Hak Dong Branch |
|
Corporate Registered No. |
110111-1159543 |
|
Business Registered No. |
214-81-89068 |
|
Permit & Licenses |
N/A |
|
Shareholder Position |
N/A |
|
Company History |
05/19/1995 Incorporated as the present name 07/26/2000 Increased the authorized shares
to 120,000 shares from 20,000 shares 10/21/2000 Moved to the present HQ address
from 1358-9, Seocho-dong, Seocho-gu, Seoul, Korea 05/16/2006 Increased capital to 700,000,000 KRW
from 400,000,000 KRW |
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Kim Yi-Yoon |
Male |
Korean |
05/19/1995 |
|
Director |
Mr. |
Lee Bok-Hee |
Male |
Korean |
05/19/1995 |
|
Director |
Mr. |
Kim Tae-Yoon |
Male |
Korean |
05/19/1998 |
|
Auditor |
M/S. |
Lee Myung-Eun |
Female |
Korean |
09/14/1998 |
Financials
The latest & full
financials are not available, and the Subject Company does not have any
obligations to release its financials to the public.
Financial Description
|
Authorized Capital(KRW) |
1,2000,000,000 |
|
Paid-Up Capital(KRW) |
700,000,000 |
|
Total Issued Shares |
70,000 |
Products, Technologies, Services Description
|
Main Products & Services |
Lactose, Ascorbic Acid |
Trade Partners & Competitors
|
Competitors |
DONGA PHARMACEUTICAL CO.,
LTD.(110111-0017990) 252, YONGDU-DONG, DONGDAEMUN-GU, SEOUL,
KOREA TEL:+82-2-920-8114 FAX:+82-2-924-2662 HANMI PHARM CO., LTD.(110111-0014409) 893-5, HAJEO-RI, PALTAN-MYEON, HWASEONG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-356-3311 FAX:+82-31-356-5151 GREEN CROSS CORPORATION(110111-0109854) 303, BOJEONG-DONG, GIHEUNG-GU, YONGIN-SI,
GYEONGGI-DO, KOREA TEL:+82-31-260-9300 FAX:+82-31-260-9413 |
Sales by Region
(Activity &
Markets)
Not Available.
Court Action
Not Available.
News Clipping
---
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.52.70 |
|
UK Pound |
1 |
Rs.82.44 |
|
Euro |
1 |
Rs.71.08 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.